Newsroom | 99588 results

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 The lower face plays a pivotal role in overall facial balance, influencing propor...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...

سان كارلوس، كاليفورنيا و ريدوود سيتي، كاليفورنيا--(BUSINESS WIRE)--أعلنت BeOne Medicines Ltd. (المدرجة في بورصة ناسداك بالرمز: ONC؛ وبورصة هونج كونج: 06160؛ وبورصة شنغهاي: 688235)، إحدى الشركات العالمية المتخصصة في علم الأورام، وRevolution Medicines, Inc. (المدرجة في بورصة ناسداك بالرمز: RVMD)، وهي شركة متخصصة في تطوير علاجات موجهة للمرضى المصابين بالسرطانات المعتمدة على RAS وفي مرحلة متقدمة من التطوير السريري، عن إبرام تعاون متعدد الأوجه يتضمن محورين رئيسيين: تعاونًا سريريًا لتقييم تركيبات دوائ...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2026. Management will host a conference call Tuesday, August 11, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 202...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026. “During the quarter, we continued to build momentum across both our RSV and immunology programs,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. “Dosing began in LOTUS, our Phase...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today reported financial and recent operational results for the second quarter ended June 30, 2026. “The second quarter of 2026 materially strengthened Rocket’s position, with the approval of KRESLADI demonstrating our ability to advance a genetic medi...

米カリフォルニア州サンカルロスおよびカリフォルニア州レッドウッドシティ--(BUSINESS WIRE)--（ビジネスワイヤ） -- 腫瘍分野でグローバルに展開するBeOne Medicines（ナスダック：ONC、香港証券取引所：06160、上海証券取引所：688235、「BeOne」）とRAS依存性癌患者向けに後期臨床段階で腫瘍標的療法を開発するRevolution Medicines（ナスダック：RVMD）は、多岐にわたる提携を発表しました。この提携には、BeOneの特定の臨床段階にある腫瘍関連の薬剤資産と、Revolution Medicinesの4種類の臨床段階にあるRAS（ON）阻害剤との併用療法を評価する臨床提携、および特定のアジア市場におけるRevolution Medicinesの薬剤資産の独占的な開発・商業化権をBeOneに付与する地域別権利契約が含まれます。 この臨床提携は、RAS依存性癌患者を対象とした標的併用療法のアプローチの可能性を模索 臨床提携の一環として開発が検討される併用療法の候補には、BeOneの特定の薬剤候補と、Revolution Medici...

SAN CARLOS, Califórnia e REDWOOD CITY, Califórnia--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), uma empresa multinacional de oncologia, e Revolution Medicines, Inc. (Nasdaq: RVMD), Uma empresa de oncologia clínica em estágio avançado que desenvolve terapias direcionadas a pacientes com tipos de câncer que dependem de RAS anunciou hoje uma cooperação de múltiplas etapas, incluindo: uma cooperação clínica para avaliar combinações de medicamentos que incorporem at...

SAN CARLOS, California, y REDWOOD CITY, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una empresa global especializada en oncología, y Revolution Medicines, Inc. (Nasdaq: RVMD), una empresa biofarmacéutica en fase clínica avanzada que desarrolla terapias dirigidas para pacientes con cánceres dependientes de RAS, anunciaron hoy una colaboración que comprende dos acuerdos. El primero es una colaboración clínica para evaluar combinaciones de determinado...